

Drugs and Aging, 2019

Supplement: Safety of Anti-Osteoarthritis Medications

Safety of cyclooxygenase-2 inhibitors in osteoarthritis: Outcomes of a systematic review
and meta-analysis

Elizabeth Curtis, Nicholas Fuggle, Sarah Shaw, Laura Spooner, Georgia Ntani, Camille
Parsons, Nadia Corp, Germain Honvo, Janis Baird, Stefania Maggi, Elaine Dennison,
Olivier Bruyère, Jean-Yves Reginster, Cyrus Cooper

ELECTRONIC SUPPLEMENTARY MATERIAL 2

Figure 9 Relative risk (RR) of lower gastrointestinal (GI) adverse events for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo





Figure 10 Relative risk (RR) of nausea/vomiting for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo



NOTE: Weights are from random effects analysis

0.006 1 162

Risk ratio
Nausea or vomiting

Figure 11 Relative risk (RR) of hypertension for COX-2 inhibitors (excluding rofecoxib) versus placebo

Cox-2 inhibitors vs Placebo





Figure 12 Relative risk (RR) of central nervous system (CNS) adverse events for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo




NOTE: Weights are from random effects analysis

0.008 1 129

Risk ratio
CNS adverse events

Figure 13 Relative risk (RR) of rash/pruritus for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo



NOTE: Weights are from random effects analysis

Risk ratio
Rash or pruritus

Figure 14 Relative risk (RR) of serious adverse events for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo





Figure 15 Relative risk (RR) of total adverse events for COX-2 inhibitors versus placebo

Cox-2 inhibitors vs Placebo



NOTE: Weights are from random effects analysis

Risk ratio
Total adverse events